List All Leukemia Trials


PCI-32765 Versus Chlorambucil Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (FH 2716)
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)
Status Conditions Phase Study ID
Closed Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Phase III FH 2716

A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

John M. Pagel, MD
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  1. Males or females of 65 years of age or greater. Patients between the ages of 65 and 70 years of age must have 1 or more of the following comorbidities that may preclude the use of frontline chemo-immunotherapy with fludarabine, cyclophosphamide, or rituximab:
    • creatinine clearance < 70 mL/min using the Cockcroft-Gault equation
    • platelet count < 100,000/μL or hemoglobin < 10 g/dL
    • clinically apparent autoimmune cytopenia (autoimmune hemolytic anemia or immune thrombocytopenia)
    • ECOG performance score = 1 or 2
  2. Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria (Hallek 2008)
  3. Active disease meeting at least 1 of the following IWCLL criteria (Hallek 2008) for requiring treatment:
    • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia Massive, progressive, or symptomatic splenomegaly
    • Massive nodes or progressive or symptomatic lymphadenopathy
    • Progressive lymphocytosis
    • Autoimmune hemolytic anemia and/or immune thrombocytopenia that is poorly responsive to corticosteroids or standard therapy
    • Constitutional symptoms
  4. Measurable nodal disease by computed tomography (CT)
  5. ECOG performance status of 0-2
  6. Life expectancy > 4 months from randomization
  7. Adequate hematologic function, defined as absolute neutrophil count (ANC) ≥ 1,000/μL (independent of growth factor support for at least 7 days prior to screening) and platelet count ≥ 50,000/μL (independent of transfusion and growth factor support for at least 7 days prior to screening)
  8. Adequate hepatic function, defined as serum aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 1.5 x ULN
  9. Adequate renal function, defined as estimated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation
  10. Willingness to receive all outpatient treatment, all laboratory monitoring, and all radiological evaluations at the institution that administers study drug for the entire study
  11. Willingness of male patients, if sexually active with a female of childbearing potential, to use an effective barrier method of contraception during the study and for 3 months following the last dose of study drug
  12. Ability to provide written informed consent and to understand and comply with the requirements of the study
Exclusions (conditions that would prevent participation in this study)
  1. Known involvement of the central nervous system by lymphoma or leukemia
  2. History or current evidence of Richter's transformation or prolymphocytic leukemia
  3. Documentation of deletion of the short arm of chromosome 17: del(17p13.1) in more than 20% of cells examined on any pretreatment fluorescence in situ hybridization (FISH) or cytogenetic evaluation
  4. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura
  5. Any previous treatment (chemotherapy, radiotherapy, and/or monoclonal antibodies) intended specifically to treat CLL/SLL
  6. Received any immunotherapy, vaccine, or investigational drug within 4 weeks prior to randomization
  7. Corticosteroid use within 1 week prior to first dose of study drug, with the exception of inhaled, topical, or other local administrations. Patients requiring systemic steroids at daily doses > 20 mg prednisone (or corticosteroid equivalent, see Appendix N), or those who are administered steroids for leukemia control or white blood cell (WBC)-count-lowering are excluded.
  8. Major surgery within 4 weeks prior to randomization
  9. History of prior malignancy, with the exception of the following:
    • malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician
    • adequately treated nonmelanomatous skin cancer or lentigo maligna melanoma without current evidence of disease
    • adequately treated cervical carcinoma in situ without current evidence of disease
  10. Currently active, clinically significant cardiovascular disease or a history of myocardial infarction within 6 months prior to randomization
  11. Inability to swallow capsules or tablets, or disease significantly affecting gastrointestinal function
  12. Uncontrolled active systemic fungal, bacterial, viral, or other infection or requirement for intravenous (IV) antibiotics
  13. Known history of infection with human immunodeficiency virus (HIV)
  14. Serologic status reflecting active hepatitis B or C infection
  15. History of stroke or intracranial hemorrhage within 6 months prior to enrollment
  16. Current life-threatening illness, medical condition, or organ-system dysfunction that could compromise patient safety or put the study at risk
  17. Requirement for anticoagulation with warfarin
  18. Requirement for treatment with a strong CYP3A4/5 and/or CYP2D6 inhibitor
Last Updated
May 12, 2014
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.